Healthcare

The US Food and Drug Administration approved Pixclara on 11 September 2026.

The Main Group includes 16 participants with mCRPC who are being evaluated for the efficacy and safety of up to six cycles of 8 GBq 67Cu-SAR-bisPSMA. This dose level was selected for the Cohort Expansion following a recommendation from the trial's Safety Review Committee.

The agreement provides an exclusive, royalty-bearing licence to commercialise the antiviral applications of Tollovir (excluding the clinical-trial formulation NLCV-001), Tollovid and NutraVir, including related formulations, data,Trade secretsand know-how. The territory is worldwide excluding China, with existing rights of TolloHealth LLC concerning Tollovid products in …

The group reported an after-tax loss of $0.1 million, compared with a $3.1 million loss in FY25.Revenuefrom continuing operations was $4.2 million, compared with $4.7 million, a decline of 10%. Software and support (SaaS) revenue grew 27% to $1.7 million and represented 41% of …

PYC Therapeutics is a clinical-stage biotechnology company creating a new generation of RNA therapies intended for patients with genetic diseases. The company states that it uses a proprietary drug delivery platform to enhance the potency of precision medicines within the RNA therapeutic class, which …

Revenue was $2,100,479 compared with $817,237 in the prior year, an increase of 157%. The company attributed the increase to the launch of its remote patient monitoring program in the United States. The loss after tax attributable to members was $14,161,734, compared with $12,679,349, …

The project aims to develop an oral complementary medication to help maintain weight loss and limit rebound weight gain after stopping medications such as GLP-1 agonists, including semaglutide. The compounds of interest are classified as Generally Regarded As Safe (GRAS) and suited to a …